Characterizing KRAS variants in NSCLC with multimodal RWD

RWD analysis reveals distinct immune and metabolic profiles among KRAS-mutant NSCLC

INDICATION
Lung
BIOMARKER
KRAS

Distribution of immune cells across KRAS variants

 

 

(A) B cells. (B) M1 macrophages. (C) M2 macrophages. (D) NK cells (E) CD8 T cells. (F) Treg cells. Statistical analysis indicates pairwise comparisons. Only q-values <0.01 are shown: **(<0.01), ***(<0.001), ****(<0.0001). No statistically significant differences were observed for percentage of neutrophils between KRAS variants.

 

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Visualization showing multiple rows of blue and orange squares, divided by a black dotted line.

Genomic and transcriptomic differences between early-onset and non-early-onset PDAC

2026-07-01
Pancreatic
KRAS
BRCA2
SMAD4
CDKN2A
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Grid displaying data points with blue, black, and gray squares on a white background.

RB1 loss-of-function mutations in post-Osimertinib NSCLC and prognostic implications

2026-07-01
Lung
RB1
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Abstract grid of small blue, gray, black, and orange squares on a white background.

Tracking PPM1D post-treatment prevalence to evaluate prognosis in lung adenocarcinoma

2026-07-01
Lung
PPM1D